Mallamaci el al. reported that one of the endogenous inhibitors of nitric oxide synthase (NOS), asymmetrical dimethylarginine, could be considered a biomarker of endothelial dysfunction and may predict all-cause and CV mortality as well as serum brain natriuretic peptide or C-reactive protein levels in patients with HD [18]. This evidence concerns the gene CRP and endothelial dysfunction.